Impact of Naturally Composed and Size-Excluded Hymenoptera Venom Preparations on the Safety and Efficacy of Venom Immunotherapy: A Monocentric Experience
International Archives of Allergy and Immunology · 2025
DOI: 10.1159/000547194 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Jörg Fischer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine, Eberhard Karls University, Tübingen, Germany, joerg.fischer@uk-augsburg.de. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Hymenoptera, Insect Bites and Stings, Hypersensitivity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The first-line treatment for patients with Hymenoptera venom allergy, a potentially life-threatening condition, is venom immunotherapy (VIT). However, for reasons still unclear, honeybee VIT (HBV-IT) is less effective than yellow jacket VIT (YJV-IT).
Methods
This retrospective monocentric study aimed to investigate the safety and efficacy of naturally composed Hymenoptera venom (NC-HV) in a rush protocol involving a high total venom dose and to compare the results with those previously obtained using size-excluded Hymenoptera venom (SE-HV). Data regarding the number of build-up cycles and maintenance of VIT with NC-HV were retrieved from institutional records. The VIT protection rate was determined by the results of the sting challenge test (SCT).
Results
We evaluated 648 individuals treated with NC-HV and compared their results with data from 1,258 individuals treated with SE-HV. The frequency of systemic reactions (SRs) with NC-HV in HBV-IT was 25.6%, and that with YJV-IT was 10.1%. Compared with previous experience with SE-HV, the use of NC-HV was associated with an increased frequency of SRs (SR rates of HBV-IT 10.4 and YJV-IT 6.3%). The protection rate in HBV-IT, as determined by SCT, was 100% with NC-HV, which is notably higher than the 95.4% previously reported with SE-HV. The efficacy of YJV-IT was equivalent to 99.0% for NC-HV and 99.6% for SE-HV.
Conclusion
Nearly complete protection was achieved with the NC-HV. The efficacy gap between HBV-IT and YJV-IT, which has limited VIT for decades, can be overcome with NC-HV in combination with a high total venom dose rush protocol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine, Eberhard Karls University, Tübingen, Germany, joerg.fischer@uk-augsburg.de.
- Department of Dermatology and Allergology, University Hospital Augsburg, Augsburg, Germany, joerg.fischer@uk-augsburg.de.
- Department of Dermatology, Faculty of Medicine, Eberhard Karls University, Tübingen, Germany.
- Department for Dermatology, University Hospital Regensburg, Regensburg, Germany.
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
- Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, Tübingen, Germany.
Zitieren
APA
Fischer, J., Löffelad, L., Kranert, P., Kneilling, M., & Volc, S. (2025). Impact of Naturally Composed and Size-Excluded Hymenoptera Venom Preparations on the Safety and Efficacy of Venom Immunotherapy: A Monocentric Experience. International Archives of Allergy and Immunology. https://doi.org/10.1159/000547194
Vancouver
Fischer J, Löffelad L, Kranert P, Kneilling M, Volc S. Impact of Naturally Composed and Size-Excluded Hymenoptera Venom Preparations on the Safety and Efficacy of Venom Immunotherapy: A Monocentric Experience. International Archives of Allergy and Immunology. 2025. doi:10.1159/000547194
BibTeX
@article{Fischer2025,
author = {Fischer, Jörg and Löffelad, Lena and Kranert, Paula and Kneilling, Manfred and Volc, Sebastian},
title = {Impact of Naturally Composed and Size-Excluded Hymenoptera Venom Preparations on the Safety and Efficacy of Venom Immunotherapy: A Monocentric Experience},
journal = {International Archives of Allergy and Immunology},
year = {2025},
doi = {10.1159/000547194}
}
EUVIMED